With the Allergan acquisition, we are bringing together more than 30
brands and leadership positions to expand and diversify our product
portfolio. This allows us to have immediate scale and profitability
to advance our innovative science pipeline that brings patients
groundbreaking medicines across a wide spectrum of therapeutic
need/critical therapeutic areas.
We continue to build a sustainable company for the long term that
provides profitable growth for shareholders, financial flexibility to
invest and expand our reach to help address the needs of people and
communities around the world.